Cidara Therapeutics, Inc.
CDTX
$220.98
$1.090.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 302.00K | 1.28M | 4.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 0.00 | 302.00K | 1.28M | 4.03M |
| Cost of Revenue | 131.82M | 108.72M | 90.56M | 71.88M | 33.02M |
| Gross Profit | -131.82M | -108.72M | -90.26M | -70.60M | -28.98M |
| SG&A Expenses | 28.09M | 24.95M | 23.20M | 20.62M | 16.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.51M | -5.51M | -5.51M | -- | -- |
| Total Operating Expenses | 154.40M | 128.16M | 108.25M | 92.49M | 49.77M |
| Operating Income | -154.40M | -128.16M | -107.95M | -91.22M | -45.74M |
| Income Before Tax | -184.80M | -117.10M | -185.59M | -170.29M | -126.10M |
| Income Tax Expenses | -- | -- | -- | -- | 7.00K |
| Earnings from Continuing Operations | -184.80 | -117.10 | -185.59 | -170.29 | -126.10 |
| Earnings from Discontinued Operations | 62.00K | -388.00K | 2.61M | 464.00K | 5.37M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -184.74M | -117.49M | -182.98M | -169.83M | -120.73M |
| EBIT | -154.40M | -128.16M | -107.95M | -91.22M | -45.74M |
| EBITDA | -154.27M | -128.02M | -107.79M | -91.07M | -45.59M |
| EPS Basic | -11.78 | -11.14 | -29.47 | -30.09 | -25.42 |
| Normalized Basic EPS | -6.48 | -7.08 | -7.16 | -7.26 | -5.02 |
| EPS Diluted | -11.78 | -11.14 | -29.47 | -30.09 | -25.43 |
| Normalized Diluted EPS | -6.48 | -7.08 | -7.16 | -7.26 | -5.02 |
| Average Basic Shares Outstanding | 66.34M | 45.98M | 35.00M | 25.36M | 20.16M |
| Average Diluted Shares Outstanding | 66.34M | 45.98M | 35.00M | 25.36M | 20.16M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |